Polaris Venture Management Co. V L.L.C. boosted its position in shares of Selecta Biosciences Inc (NASDAQ:SELB) by 72.6% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The firm owned 2,773,479 shares of the company’s stock after buying an additional 1,166,666 shares during the quarter. Selecta Biosciences makes up 5.6% of Polaris Venture Management Co. V L.L.C.’s holdings, making the stock its 5th biggest position. Polaris Venture Management Co. V L.L.C. owned about 6.19% of Selecta Biosciences worth $6,573,000 at the end of the most recent quarter.
Other hedge funds have also recently added to or reduced their stakes in the company. Barclays PLC lifted its holdings in Selecta Biosciences by 87.6% during the fourth quarter. Barclays PLC now owns 12,661 shares of the company’s stock valued at $34,000 after purchasing an additional 5,911 shares in the last quarter. Rhumbline Advisers lifted its holdings in Selecta Biosciences by 50.3% during the fourth quarter. Rhumbline Advisers now owns 23,802 shares of the company’s stock valued at $63,000 after purchasing an additional 7,965 shares in the last quarter. Two Sigma Advisers LP lifted its stake in shares of Selecta Biosciences by 18.3% in the fourth quarter. Two Sigma Advisers LP now owns 54,900 shares of the company’s stock worth $146,000 after buying an additional 8,500 shares in the last quarter. Deutsche Bank AG lifted its stake in shares of Selecta Biosciences by 251.6% in the fourth quarter. Deutsche Bank AG now owns 127,121 shares of the company’s stock worth $337,000 after buying an additional 90,970 shares in the last quarter. Finally, Geode Capital Management LLC lifted its stake in shares of Selecta Biosciences by 17.9% in the fourth quarter. Geode Capital Management LLC now owns 175,308 shares of the company’s stock worth $466,000 after buying an additional 26,568 shares in the last quarter. Institutional investors own 49.67% of the company’s stock.
Several equities analysts have recently weighed in on SELB shares. Zacks Investment Research raised shares of General Moly from a “sell” rating to a “hold” rating in a research note on Thursday, July 11th. ValuEngine downgraded shares of Zumiez from a “hold” rating to a “sell” rating in a research note on Tuesday, July 2nd. Finally, Mizuho set a $88.00 target price on shares of Gilead Sciences and gave the stock a “buy” rating in a research note on Friday, May 10th. Two analysts have rated the stock with a sell rating, two have issued a hold rating and five have given a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average price target of $8.04.
Selecta Biosciences (NASDAQ:SELB) last announced its quarterly earnings data on Thursday, May 9th. The company reported ($0.31) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.37) by $0.06. The business had revenue of $0.01 million during the quarter. Sell-side analysts expect that Selecta Biosciences Inc will post -1.35 EPS for the current fiscal year.
Selecta Biosciences Profile
Selecta Biosciences, Inc, a clinical-stage biopharmaceutical company, researches and develops nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Its proprietary pipeline includes therapeutic enzymes, gene therapies, and other products and product candidates affected by undesired immune responses.
Featured Story: How to Profit and Limit Losses With Stop Orders
Receive News & Ratings for Selecta Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Selecta Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.